News | September 27, 2024
Avient expands healthcare TPU manufacturing in China
Showcases specialty and sustainable materials for healthcare at Medtec China 2024
Showcases specialty and sustainable materials for healthcare at Medtec China 2024
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
Eugia Steriles receives EIR from USFDA for new injectable facility
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Subscribe To Our Newsletter & Stay Updated
